Patient must have fully recovered from the effects of prior surgery at least days prior to sub-study registration Patients may have received prior surgery; at least days must have elapsed since surgery and patient must have recovered from any adverse effects of surgery Surgery (partial or gross total resection or biopsy) must be performed >= weeks prior to registration; patient must have recovered adequately from the effects of surgery The patient must have recovered from effects of surgery, postoperative infection, and other complications within days prior to step registration Recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy Recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy to CTCAE v. grade , baseline or less, except for alopecia Subject has recovered (i.e., to Grade ? or to a baseline level) from the effects of surgery, radiotherapy, chemotherapy, hormonal therapy, or other therapies for cancer; with the exception of vitiligo, alopecia, neuropathy, partial hearing loss, and/or endocrinopathies (for which no resolution is required); Major surgery =< weeks prior to registration or who have not recovered from side effects of such therapy; subjects must have recovered from any effects of recent radiotherapy that might confound the safety evaluation of study drug Patients must have recovered from effects of recent surgery, radiotherapy, or chemotherapy; they should be free of significant infection Subjects must have recovered from major side effects of prior therapies or procedures. The patient must have recovered from the effects of surgery, postoperative infection and other complications before enrollment; Patients must be at least weeks from radiation or surgery and recovered from all ill effects Patients with a recent surgery should have recovered from all effects of the surgery and be cleared by their surgeon Must have recovered from effects of surgery, postoperative infection and other complications of surgery Patients must have recovered from effects of recent surgery, radiotherapy, or chemotherapy Must have recovered from adverse effects of any prior surgery, radiotherapy or other antineoplastic therapy Subject who has received radiotherapy < days prior to registration, and who has not recovered to grade or better from related side effects of such therapy (exceptions include alopecia). Any patient who has had a recent surgery should have recovered from all effects of the surgery and be cleared by their surgeon Incomplete recovery from acute effects of any surgery prior to treatment. Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment Patients must be deemed by the investigators to be fully recovered from both acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapy Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment PHASE I: Recovery from effects of recent surgery, radiotherapy, or chemotherapy must be demonstrated PHASE II: Recovery from effects of recent surgery, radiotherapy, or chemotherapy must be demonstrated Not recovered to Grade from adverse effects of prior myeloma therapy or radiotherapy prior to screening. Previous chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected; the subject should have recovered from the effects of these or of any prior surgery Subjects having undergone recent resection or biopsy of an intracranial tumor will be eligible as long as all of the following conditions apply: \r\n* First dose of cabozantinib occurs at least days after surgery, and the subject has recovered from the effects of surgery Recovered from effects of any prior surgery or cancer therapy Patients must not have chemotherapy, radiotherapy, chemoembolization, radioembolization, or immunoembolization for their malignancy within days prior to treatment and must have recovered from all side effects of therapeutic and diagnostic interventions except those listed in Appendix B of the study protocol. Have recovered from the effects of any prior radiotherapy or surgery; At least weeks and recovery from effects of prior surgery, prior radiotherapy, or other therapy with an approved or investigational agent Participant must have recovered from the effects of surgery, postoperative infection, and other complications; has no significant post-operative hemorrhage. Recovery from effects of recent surgery, radiotherapy, or chemotherapy Patients must be recovered from both the acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapy Patients must be recovered from both the acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapy Patients must have recovered from effects of recent surgery, radiotherapy or chemotherapy Subjects must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer. Patient must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer Patients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure. Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior system anticancer therapy, radiotherapy or surgery. Patients must be recovered from effects of recent surgery ( days must elapse between surgery and the start of treatment with cabozantinib) Patients with recent resection for recurrent disease must have recovered from the effects of surgery and should not start treatment for at least days after surgery Patients may have received prior surgery; however, at least days must have elapsed since completion of surgery and the patient must have recovered from all side effects The patient must have recovered from the effects of surgery, post-operative infection, and other complications before study registration. Recovered from effects of recent surgery, radiotherapy, or chemotherapy Patients must have had no chemotherapy, radiotherapy, or biologic therapy for their malignancy in the month prior to treatment and must have recovered from all side effects of therapeutic and diagnostic interventions Participants must have recovered from the acute effects of chemotherapy and radiotherapy and from surgical side effects following definitive breast surgery. The patient is, in the investigator's opinion, adequately recovered from the effects of surgery and chemoradiotherapy to participate in this study. Subjects who have not recovered from the effects of recent surgery Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy, up to CTCAE grade Patient must have recovered sufficiently from any adverse effects of neoadjuvant treatment Patient must have recovered sufficiently from any adverse effects of neoadjuvant treatment Patients must be recovered from acute and late effects of any prior surgery, radiotherapy or other anti-neoplastic therapy Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy or surgery Recovery from effects of recent surgery, radiotherapy, or chemotherapy Patients must have recovered from the effects of prior surgery. Recovered from the effects of any prior systemic therapy, radiotherapy or surgery Must have recovered from all side effects of their most recent systemic or local treatment Patients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure. Recovery from the effects of surgery. Recovered from effects of recent surgery, radiotherapy, and chemotherapy Patients must be recovered from the effects of any prior surgery, radiotherapy, or other antineoplastic therapy Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy. Up to CTCAE Grade is acceptable for patients with known peripheral neuropathy Previous chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected, but the subject should have recovered from the effects of these or of any prior surgery; chemotherapy can be within days of operation Previous chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected, but the subject should have recovered from the effects of these or of any prior surgery Patients having undergone recent resection (within weeks prior to registration) of their glioblastoma to treat current recurrence prior to study treatment must have recovered from the effects of surgery (including patient's skin having fully recovered from the surgical wound) Note: a -week window is required after surgery prior to starting treatment. For CNS-related stereotactic biopsies, a minimum of days must have elapsed prior to registration. Patients must have completed mastectomy or breast-sparing surgery and must have recovered from all side effects of the surgery; if patients were treated with chemotherapy and/or radiation therapy, these treatments must be completed at least days prior to study registration; patients should have recovered from all grade or higher side effects of chemotherapy and/or radiation therapy with the exception of alopecia and peripheral neuropathy; concurrent bisphosphonate and trastuzumab therapies are allowed Recovered from the effects of any prior surgery or radiotherapy